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1. Introduction 
Cyclic AMP has been proposed as the active agent 
in induction of tyrosine aminotransferase ([ 1,2] ; TAT: 
EC 2.6.1 S), increased uptake of a-aminoisobutyrate 
[3-51 ,AIB) or both [6,7]. However, none of these 
studies have demonstrated that cyclic AMP levels 
change either before or co-incident with the increases 
in either TAT activity or AIB uptake. This is an 
essential requirement which must be fulfilled before a 
role for cyclic AMP can be established [8] . This paper 
reports the results of concurrent measurements of 
cyclic AMP, TAT, and AIB uptake in rat livers at 
various times after the injection of glucagon. These 
results indicate that hepatic cyclic AMP levels do 
increase after injections of glucagon before increases 
in TAT activity and AIB uptake are observed. 
2. Materials and methods 
Rats were obtained from the Charles River 
Breeding Laboratories (Wilmington, Massachusetts, 
USA) at 36 days of age. The rats were housed in a 
windowless room with the lighting regulated to give 
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alternating 12 hr periods of light and dark and were 
given a 30% protein diet on an ‘8 t 16’ feeding sche- 
dule [9] . No food was available for 18 hr before the 
experiments were begun, and food was withheld 
during the experiments. The rats were injected with 
either 0.2 mg glucagon in 0.5 ml of isotonic NaCl 
per 100 g of body weight, given subcutaneously 
instead of intraperitoneally on the basis of previous 
experiments [ 12],9.0 mg theophylline in 1 .O ml of 
saline per 100 g of body weight, given intraperitoneal- 
ly; or both glucagon and theophylline. Those animals 
not receiving injections of both glucagon and theo- 
phylline were given a balancing injection of saline 
such that each animal received the same number of 
injections and the same volume per 100 g body weight. 
Rats were killed by decapitation and the blood was 
collected in beakers containing heparin. The livers 
were quickly excised and frozen in liquid nitrogen. 
The livers were powdered, weighed and rapidly homo- 
genized in either 5% TCA (v/v), for cyclic AMP sam- 
ples or in 0.15 M NaCl for TAT samples. The injec- 
tion of AIB as well as the preparation of the enzyme 
and plasma samples was as previously described [6] . 
TAT was assayed by the procedure of Diamondstone 
[IO] . The preparation and subsequent assay of the 
cyclic AMP was as described elsewhere [ 111. The AIB 
data are expressed as the ratio between the dpm per 
g liver and the dpm per ml of plasma. 
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Fig. 1. Time course following cyclic AMP levels in rat liver 
after injection of: glucagon (G), theophylline (T), glucagon 
plus theophylline (G+T), or saline (S). The doses are given in 
the text. The data are expressed as the mean k standard error 
of values from 3 animals per time point. The standard error 
falls within the character for those points where no standard 
error is indicated. The dashed lines between the 20 min and 
1.5 hr time points indicate the decline of cyclic AMP concen- 
tration, after injection of glucagon, which we have observed in 
other experiments. 
3. Results 
The results in fig. 1 show that glucagon increases 
the hepatic level of cyclic AMP SO-fold above the 
control at 20 min. If theophylline, an inhibitor of 
the phosphodiesterase [8] , is injected with the 
glucagon the hepatic cyclic AMP levels are increased 
to 120 times the control value at 20 min. Subsequent 
to the 20 min time point the levels decline to 1.4 
and 4.5 times the control at 1.5 hr for the animals 
receiving glucagon and glucagon plus theophylline 
respectively. Theophylline increased the level of 
hepatic cyclic AMP to three times the control at 1.5 
hr. A detailed time course for the effect of theophyl- 
line or glucagon on hepatic AMP levels will be repor- 
ted in detail elsewhere [ 121. 
Data in fig. 2 shows the level of TAT and of AIB 
uptake at 1.5 hr and 3 .O hr after the various treat- 
ments. Measurements of AIB uptake at 20 min (not 
shown) have previously established that there is no 
effect of glucagon and a slight effect of glucagon plus 
theophylline on the liver/plasma ratio due to a drop 
in the plasma level of AIB. Similarly, there is no 
effect of glucagon plus theophylline on TAT activity 
at 20 min (not shown). The differences in the 
means of the AIB uptake or of TAT activity at 1.5 
or at 3 hr are not significantly different, within either 
of the individual time points, except for AIB uptake 
at 1.5 hr after injection of glucagon. 
Comparison of data in figs. 1 and 2 demonstrates 
that the hepatic cyclic AMP levels change in response 
to glucagon or glucagon plus theophylline before 
significant changes are observed in either TAT of AIB. 
4. Discussion 
Sutherland et al. [8] have proposed a series of 
criteria which must be fulfilled before cyclic AMP 
can be considered the mediator of a hormonal res- 
ponse. One of these criteria requires that the intra- 
cellular concentration of cyclic AMP should either 
increase before or at least coincident with the response 
studied. In the present report the responses studied 
were TAT activity and AIB uptake. It was demons- 
trated that the hepatic cyclic AMP levels increase in 
response to glucagon or glucagon plus theophylline 
before an increase in either TAT or AIB uptake is 
observed; thus, satisfying one of the criteria stated 
by Sutherland et al. [8]. 
A previous report from this laboratory [6] has 
stated that injection of dibutyryl AMP increases 
both TAT and AIB uptake. These findings satisfy 
another criterion of Sutherland et al. [8] which states 
that cyclic AMP or dibutyryl cyclic AMP should eli- 
cit the response(s) directly. 
Another criterion of Sutherland [8] states that 
the responses tudied should be potentiated by the 
addition of phosphodiesterase inhibitors. We do not 
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course following changes in TAT activity and AIB distribution ratio. Characters are as described in legend 
The data are expressed as the mean + the standard error of values from 3 animals per group. 
to fig. 1. 
obtain a potentiation of the effect of glucagon on TAT 
activity or on AIB uptake when theophylline, an 
inhibitor of the phosphodiesterase, is given with 
glucagon; however, theophylline plus glucagon gives 
a much greater increase in hepatic cyclic AMP levels 
than does glucagon alone. This can be explained if 
one assumes that the systems responsible for induc- 
tion of TAT and increased AIB uptake can be satu- 
rated with respect to cyclic AMP. Thus, increasing 
the concentration of cyclic AMP above the satura- 
ting concentration would not lead to a greater res- 
ponse. If, in the present study, glucagon alone gave 
a concentration of cyclic AMP which would maxi- 
mally induce TAT and AIB uptake, then a further 
increase in the concentration of cyclic AMP should 
not give a higher level of TAT activity or AIB uptake. 
Although the data of this report and of a previous 
report from this laboratory [6] strongly suggest cyclic 
AMP as the mediator of the induction of TAT and of 
increased AIB uptake by glucagon, alternative approa- 
ches should still be pursued. Such approaches should 
consider the possible involvement of calcium as has 
been proposed by Rasmussen [ 131. In addition rea- 
gents which will block the action of glucagon on 
adenyl cyclase or inhibit adenyl cyclase directly should 
be sought as an alternative approach. 
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